Home > PE Ratio > GLAND PHARMA

GLAND PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of GLAND PHARMA is 41.90.

Share Price ₹1,958.2Aug 22,2025
Market Cap ₹32,271.1 Cr
Earnings-TTM₹770.2 CrTTM-Consolidated Results
Price/Earnings41.90xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results
GLAND PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of GLAND PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of GLAND PHARMA is calculated as :

Current Market Cap [ ₹32,271.1 Cr] as on Aug 22,2025

(/) Earnings [ ₹770.2 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 41.90x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for GLAND PHARMA , the investors are currently willing to pay 41.90 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAND PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of GLAND PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of GLAND PHARMA


PE Ratio Performance Analysis for GLAND PHARMA

- GLAND PHARMA 's latest p/e ratio is 41.90x.

- GLAND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.71x.

- GLAND PHARMA 's operated at median p/e ratio of 39.27x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, GLAND PHARMA 's p/e ratio peaked in Mar2022 at 44.33x.

- GLAND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 26.75x.


How does GLAND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
GLAND PHARMA 770.2541.9032,271.1
SUN PHARMACEUTICAL INDUSTRIES LTD10,411.5037.86394,187.0
DIVIS LABORATORIES LTD2,306.0070.81163,282.0
CIPLA LTD5,406.8123.79128,619.0
TORRENT PHARMACEUTICALS LTD2,002.0062.29124,712.0
DR REDDYS LABORATORIES LTD5,726.7018.61106,577.0
MANKIND PHARMA LTD1,905.5156.45107,559.0
ZYDUS LIFESCIENCES LTD4,637.8021.4599,496.4
LUPIN LTD3,722.1824.2490,234.1
AUROBINDO PHARMA LTD3,417.9317.8560,998.7
ABBOTT INDIA LTD1,452.2946.6967,806.0

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAND PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 17.85x
Max industry PE 70.81x
Median industry PE 37.86x
Average industry PE 38.36x



You may also like the below Video Courses